Skip to main content
Erschienen in: Supportive Care in Cancer 12/2018

31.05.2018 | Original Article

Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction

verfasst von: Ru-jun Zheng, Yan Fu, Jiang Zhu, Jiu-ping Xu, Qiu-fen Xiang, Lin Chen, Hua Zhong, Jun-ying Li, Chun-hua Yu

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Patients with cancer often experience pain that affects their daily activities and quality of life. The analgesic ladder recommended by the World Health Organization has proved insufficient for many, and its scientific basis has been questioned. This retrospective study investigated factors related to adherence to long-term opioid therapy for patients with moderate cancer pain, including an evaluation of low-dose morphine relative to tramadol.

Methods

Clinical data were collected of patients with moderate cancer pain (n = 353) who received either low-dose morphine or tramadol and were followed for ≥ 27 weeks. Factors related to regime adherence were investigated, including the analgesia type, cancer therapy (antitumor therapy or palliative care), pain type (nociceptive, neuropathic, or mixed), and living distance to the hospital. Factors related to clinically meaningful pain reduction (≥ 30% reduction in pain from baseline) were also investigated.

Results

Patients taking tramadol, receiving antitumor therapy, experiencing neuropathic pain, and living far from the hospital were more likely to change analgesic strategy compared with, respectively, patients receiving low-dose morphine, palliative care, experiencing nociceptive pain, and living nearby. Factors that increased the likelihood of adherence to the analgesic regime were also associated with the likelihood of clinically meaningful pain reduction. Among adverse effects, a significantly higher percentage of patients experienced constipation in the tramadol group compared with those given morphine.

Conclusions

Among patients with moderate cancer pain, long-term low-dose morphine was safe and more effective than tramadol for clinically meaningful pain reduction, and patients were less likely to change the analgesic strategy.
Literatur
1.
Zurück zum Zitat WHO Expert Committee (1990) Cancer pain relief and palliative care. World Health Organ Tech Rep Ser 804:1–75 WHO Expert Committee (1990) Cancer pain relief and palliative care. World Health Organ Tech Rep Ser 804:1–75
2.
Zurück zum Zitat DeAndrea S, Monatanari M, Moja L et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRef DeAndrea S, Monatanari M, Moja L et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRef
3.
Zurück zum Zitat Mercadante S, Fulfaro F (2005) World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16:iv132–iv135CrossRef Mercadante S, Fulfaro F (2005) World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16:iv132–iv135CrossRef
4.
Zurück zum Zitat Ferreira KASL, Kimura M, Teixeira MJ (2006) The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 14:1086–1093CrossRef Ferreira KASL, Kimura M, Teixeira MJ (2006) The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Support Care Cancer 14:1086–1093CrossRef
5.
Zurück zum Zitat Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, de Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRef Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, de Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G, European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC) (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68CrossRef
6.
Zurück zum Zitat Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D, Fabbri L, Nanni O, Raulli P, Poggi B, Fochessati F, Giannunzio D, Barbagallo ML, Minnotti V, Betti M, Giordani S, Piazza E, Scapaticci R, Ferrario S (2005) A validation study of the WHO analgesic ladder: a two-step cf. three-step strategy. Support Care Cancer 13:888–894CrossRef Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D, Fabbri L, Nanni O, Raulli P, Poggi B, Fochessati F, Giannunzio D, Barbagallo ML, Minnotti V, Betti M, Giordani S, Piazza E, Scapaticci R, Ferrario S (2005) A validation study of the WHO analgesic ladder: a two-step cf. three-step strategy. Support Care Cancer 13:888–894CrossRef
7.
Zurück zum Zitat Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manag 27:409–416CrossRef Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manag 27:409–416CrossRef
8.
Zurück zum Zitat Sloman R, Wruble AW, Rosen G, Rom M (2006) Determination of clinically meaningful levels of pain reduction in patients experiencing acute postoperative pain. Pain Management Nursing 7(4):153–158CrossRef Sloman R, Wruble AW, Rosen G, Rom M (2006) Determination of clinically meaningful levels of pain reduction in patients experiencing acute postoperative pain. Pain Management Nursing 7(4):153–158CrossRef
9.
Zurück zum Zitat Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpfe A, Petzke F (2014) Long-term opioid use in non-cancer pain. Dtsch Arztebl Int 111(43):732–740PubMedPubMedCentral Häuser W, Bock F, Engeser P, Tölle T, Willweber-Strumpfe A, Petzke F (2014) Long-term opioid use in non-cancer pain. Dtsch Arztebl Int 111(43):732–740PubMedPubMedCentral
10.
Zurück zum Zitat Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manag 18:174–179CrossRef Grond S, Radbruch L, Meuser T, Loick G, Sabatowski R, Lehmann KA (1999) High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manag 18:174–179CrossRef
11.
Zurück zum Zitat Kim HJ, Kim YS, Park SH (2015) Opioid rotation compared with combination for cancer patients with chronic uncontrolled pain: a randomized study. BMC Palliative Care 14(1):1–6CrossRef Kim HJ, Kim YS, Park SH (2015) Opioid rotation compared with combination for cancer patients with chronic uncontrolled pain: a randomized study. BMC Palliative Care 14(1):1–6CrossRef
12.
Zurück zum Zitat Moksnes K, Kaasa S, Paulsen Ø, Rosland JH, Spigset O, Dale O (2012) Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. Eur J Clin Pharmacol 68(8):1147–1156CrossRef Moksnes K, Kaasa S, Paulsen Ø, Rosland JH, Spigset O, Dale O (2012) Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. Eur J Clin Pharmacol 68(8):1147–1156CrossRef
13.
Zurück zum Zitat Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, Manfredi P (2001) Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 92(7):1919–1925CrossRef Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, Manfredi P (2001) Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 92(7):1919–1925CrossRef
14.
Zurück zum Zitat Eisemberg E, Berkey CS, Carr DB et al (1994) Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12:2756–2765CrossRef Eisemberg E, Berkey CS, Carr DB et al (1994) Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12:2756–2765CrossRef
15.
Zurück zum Zitat Minotti V, de Angelis V, Rigetti E et al (1998) Double blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 74:133–137CrossRef Minotti V, de Angelis V, Rigetti E et al (1998) Double blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 74:133–137CrossRef
16.
Zurück zum Zitat Lowery AE, Greenberg MA, Foster SL, Clark K, Casden DR, Loscalzo M, Bardwell WA (2012) Validation of a needs-based biospychosocial distress instrument for cancer patients. Psychooncology 21:1099–1106CrossRef Lowery AE, Greenberg MA, Foster SL, Clark K, Casden DR, Loscalzo M, Bardwell WA (2012) Validation of a needs-based biospychosocial distress instrument for cancer patients. Psychooncology 21:1099–1106CrossRef
17.
Zurück zum Zitat Xuemei L, Huaiqing L, Hengjiang G (2002) Epidural patient control using tramadol compared with morphine for postoperative cancer pain. Mod Med Health 18:122–123 Xuemei L, Huaiqing L, Hengjiang G (2002) Epidural patient control using tramadol compared with morphine for postoperative cancer pain. Mod Med Health 18:122–123
18.
Zurück zum Zitat Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M, the Early Strong Opioid Treatment Study Investigators (2016) Randomized trial of low-dose morphine compared with weak opioids in moderate cancer pain. J Clin Oncol 34(5):436–442CrossRef Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M, the Early Strong Opioid Treatment Study Investigators (2016) Randomized trial of low-dose morphine compared with weak opioids in moderate cancer pain. J Clin Oncol 34(5):436–442CrossRef
19.
Zurück zum Zitat Seow H, Bainbridge D (2018) A review of the essential components of quality palliative care in the home. J Palliat Med 21(S1):S37–S44CrossRef Seow H, Bainbridge D (2018) A review of the essential components of quality palliative care in the home. J Palliat Med 21(S1):S37–S44CrossRef
20.
Zurück zum Zitat Oh SY, Shin SW, Koh SJ et al (2017) Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Support Care Cancer 25(12):1–9CrossRef Oh SY, Shin SW, Koh SJ et al (2017) Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Support Care Cancer 25(12):1–9CrossRef
22.
Zurück zum Zitat Lampl C, Schweiger C, Haider B, Lechner A (2010) Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. J Neurol 257(8):1265–1273CrossRef Lampl C, Schweiger C, Haider B, Lechner A (2010) Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study. J Neurol 257(8):1265–1273CrossRef
Metadaten
Titel
Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction
verfasst von
Ru-jun Zheng
Yan Fu
Jiang Zhu
Jiu-ping Xu
Qiu-fen Xiang
Lin Chen
Hua Zhong
Jun-ying Li
Chun-hua Yu
Publikationsdatum
31.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4282-2

Weitere Artikel der Ausgabe 12/2018

Supportive Care in Cancer 12/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.